Chicago: October 14, 2017
Seats are available for Labrix Core Training in Chicago. Registration is just $150 and includes a free Adrenal Function Panel ($100 value) Register today.
Las Vegas, NV: February 9-11, 2018
Early Bird Discount: Save $50
Interested in gaining a deeper understanding of how hormone and neurotransmitter imbalances are affecting your patient’s health? Register today for the Labrix Advanced Workshop to lock in your early bird discount price of $229, a savings of $50! Includes a Free NeuroAdrenal Panel (Value $215).
Portland, OR: September 22-24, 2017
Labrix representatives will be exhibiting at the LDN 2017 Conference in Portland, OR in a few days. Come and learn what testing with Labrix is all about.
Tucson, AZ: October 5-8, 2017
Labrix founder, Dr. Erin Lommen, will be flying to the beautiful city of Tuscon, AZ, to speak at the 15th Annual AARM Conference in mid September. Come take in the sunshine and learn more about adrenal health and minimizing inflammation.
Denver, CO: October 19-24, 2017
Labrix will be in Colorado for the IFM Conference on October 19-24. Come chat with our booth representative and learn more about testing with Labrix.
San Diego, CA : October 22-25, 2017
Labrix co-founder and Chief Clinical Consultant Erin Lommen ND will be speaking on October 22-25 at the AIHM Conference in San Diego, CA. Stop by the Labrix and Doctor's Data booth and learn more about testing with Labrix.
Methylation and Mood Support
Methylation is a chemical step that involves the addition of a methyl group (CH4) to a compound in the body and is involved in many biochemical pathways, although it is most well-known as part of the cycle where homocysteine is converted to methionine. These reactions require a methyl donor – a molecule that can give up a methyl group to be attached to another molecule. Common methyl donors are L-methylfolate and methylcobalamin (methyl B12), which are methylated forms of the dietary B vitamins folate and B12. Methylfolate is required to produce methyl B12, and the enzyme methylenetetrahydrofolate reductase (MTHFR) is required to convert dietary folate to methylfolate.
Unfortunately for many, there are several common polymorphisms in the gene that codes for MTHFR that result in compromised ability to convert folate to the active (methylated) form. The consequences of the most well-known variants are similar to that of reduced dietary folate intake; however, diet changes or supplementation of folate will not remedy the situation. Correction must include direct supplementation with the methylated form of these nutrients. The frequency of MTHFR polymorphisms varies depending on geographical regions and various populations, but may be as prevalent as 50% in some regions.
Though methylation is well known for its role in pregnancy, cardiovascular health, inflammation and detoxification, recent literature explores and emphasizes its role in mood support, clearly demonstrating a correlation between decreased methylation ability and major depression, schizophrenia and bipolar disorder. Methylfolate displays anti-depressant effects via its roles in the central nervous system and is a critical co-factor for neurotransmitter synthesis. Specifically, methylfolate combines with BH2 utilizing the MTHFR enzyme to produce tetrahydrobiopterin (BH4) which is required by the rate limiting enzymes of monoamine neurotransmitter synthesis (serotonin, dopamine, norepinephrine and epinephrine). As such, it is essential for the production of these mood-regulating neurotransmitters. Methylfolate displays additional antidepressant activity via its role in the homocysteine cycle where the transformation of homocysteine to methionine requires methylcolbalamin and methylfolate. Methionine is then converted to SAMe which is the methyl donor for all monoamines.
Supporting methylation has proven to be effective in decreasing and, in some cases, resolving depressive symptoms with or without concomitant antidepressant therapies. This supportive therapy may be particularly beneficial when neurotransmitter testing reveals low to low range serotonin, dopamine, norepinephrine and/or epinephrine levels.
Farah, MD FAPA An expert review of clinical challenges in psychiatry CNS Spectr. 2009; 16:1 (Suppl 2): 10-7 2.
Gilbody S, Lewis S, Lightfoot T. Methylentetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007 Jan 1; 165(1):1-13 3.
Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Alt Med Review. 2008; 13(3), 216-226. 4.
Zappacosta B, Romano L, Persichilli S et al. Genotype prevalence and allele frequencies of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in Italian newborns. LabMedicine. 2009 Dec; 40(12), 732-736.
All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.
Labrix Core Training
Join the hundreds of practitioners who have attended Labrix live training events and learn more about these exciting opportunities directly from a Labrix attendee and Dr. Jay Mead, Medical Director and co-founder of Labrix.